Abstract
Umbilical cord blood (CB) is being used increasingly as a source of hematopoietic support for patients with high-risk hematologic diseases lacking a human leukocyte antigen (HLA)-matched bone marrow donor. The first successful CB transplant was performed in 1989 by Dr. Gluckman and colleagues [1]. Since then, more than 20,000 CB transplants (CBTs) have been performed world-wide in pediatric and adult patients. The ethnic diversity, relative ease of collection, and ready availability as cryopreserved units, as well as tolerance of higher degrees of HLA disparity between donor and recipient, are positive attributes of CB when compared to bone marrow or mobilized peripheral blood progenitor cells (PBPCs).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
